Gilead Beats and Prints a Record High, But the 2026 Guide Lands Light: Initiating at Hold
Key Takeaways
- Clean top-and-bottom beat. Q4 product sales of $7.9B (+5% YoY) topped the ~$7.6B Street bar, and non-GAAP EPS of $1.86 edged the $1.83 consensus, powered by a record $5.8B HIV quarter and a 17% jump in liver disease.
- The stock told two stories in 18 hours. GILD dropped as much as ~5.8% after hours on a 2026 guide that sat at the low end of Street models, then reversed to close +5.8% at a record $155.80 the next session as the Street re-read the print as a clean base-business beat.
- 2026 guide embeds real policy drag. Management guided base business to 4–5% growth and EPS to $8.45–$8.85, absorbing a ~2-point HIV growth headwind from the Medicaid pricing agreement and ACA subsidy expiry; absent those, they framed underlying growth at 6–7%.
- Yeztugo is the swing factor. The twice-yearly PrEP injectable hit 90% payer coverage well ahead of target and is guided to ~$800M in 2026 (from $150M), a number some on the Street already call conservative; Kite cell therapy, guided down ~10%, is the offsetting drag.
- Rating: Initiating at Hold. This is a de-risked, cash-generative franchise with no major patent cliffs until 2036, but the stock has already re-rated +54% over twelve months to a record high above the Street's median target on an in-line guide. We want a better entry or a guidance raise before paying up.
Results vs. Consensus
| Metric (Q4 2025) | Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Total product sales | $7.9B | $7.6B | Beat | +3.9% |
| Product sales ex-Veklury | $7.7B | n/a | Beat | +7% YoY |
| Non-GAAP EPS | $1.86 | $1.83 | Beat | +1.6% |
| Product gross margin (non-GAAP) | 86.8% | ~86.7% | In line | +10bps YoY |
| Trodelvy | $384M | $362M | Beat | +6.1% |
| Yeztugo (YES2GO) | $96M | ~$106M (whisper) | Miss vs. whisper | -9% |
| Year-over-year (Q4) | Q4 2025 | Q4 2024 | Change |
|---|---|---|---|
| Total product sales | $7.9B | ~$7.5B | +5% |
| Product sales ex-Veklury | $7.7B | ~$7.2B | +7% |
| HIV | $5.8B | ~$5.5B | +6% |
| Non-GAAP EPS | $1.86 | $1.90 | -2% |
| R&D (non-GAAP) | $1.6B | ~$1.6B | Flat / -3% |
| SG&A (non-GAAP) | $1.7B | $1.9B | -9% |
| Sequential (QoQ) | Q4 2025 | Q3 2025 | Change |
|---|---|---|---|
| Total product sales | $7.9B | ~$7.3B | +8% |
| HIV | $5.8B | ~$5.3B | +10% |
| Liver disease | $844M | ~$819M | +3% |
| Cell therapy (Kite) | $458M | ~$432M | +6% |
Quality of Beat/Miss
- Revenue: High quality on the base business. Ex-Veklury sales rose 7% YoY, and the beat was demand-led across HIV and liver rather than a one-time item. The caveat: HIV's +10% sequential print was flattered by seasonal channel inventory build and favorable mix, both of which management flagged as reversing into the normal Q1 drawdown.
- Margins: Sustainable. Non-GAAP product gross margin held at 86.8%, and SG&A fell 9% YoY on lower G&A and legal spend, evidence the operating-discipline story is intact even while the company funds the Yeztugo launch. The 2026 guide steps gross margin up to ~87%.
- EPS: The 2% YoY decline is optical. It reflects the timing of a $539M acquired-IPR&D charge (Interius acquisition plus the Shenzhen Pregene collaboration), not operating erosion. Underlying operating EPS grew; the full-year non-GAAP figure of $8.15 (up from $4.62 in 2024, which carried the Simbae/CymaBay charge) makes the point.
Segment Performance
| Franchise | Q4 2025 sales | YoY | QoQ | FY2025 | FY YoY |
|---|---|---|---|---|---|
| HIV (total) | $5.8B | +6% | +10% | $20.8B | +6% |
| — Biktarvy | $4.0B | +5% | n/a | $14.3B | +7% |
| — Descovy | ~$780M | +33% | n/a | $2.8B | +31% |
| — Yeztugo | $96M | launch | n/a | $150M | launch |
| Liver disease | $844M | +17% | +3% | $3.2B | +6% |
| — Livdelzi | $150M | ramp | +42% | n/a | ramp |
| Oncology (Trodelvy) | $384M | +8% | +8% | $1.4B | +6% |
| Cell therapy (Kite) | $458M | -6% | +6% | $1.8B | -7% |
| Veklury | $212M | decline | n/a | $911M | -49% |
| Total product sales | $7.9B | +5% | +8% | $28.9B | +1% |
HIV — the engine, running on demand and mix
HIV delivered a record $5.8B quarter, up 6% YoY and 10% sequentially, and $20.8B for the full year. Biktarvy remains the franchise anchor at $4.0B in Q4 and $14.3B for 2025, with U.S. share above 52% and year-over-year share gains every quarter since launch. The prevention side is where the story is inflecting: Descovy PrEP grew 33% in the quarter to record U.S. share above 45%, and the full-year HIV number would have grown 10% rather than 6% absent the ~$900M Medicare Part D redesign headwind.
"Our HIV business delivered record sales of $5.8 billion for the fourth quarter, up 6% year over year... Excluding the estimated $900 million headwind associated with the Medicare Part D redesign, our HIV business grew 10% year over year." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer
Assessment: The base HIV franchise is doing exactly what a durable annuity should: mid-single-digit demand growth with share gains and no LOE in sight. The 10% sequential jump is not the run-rate, though: management was explicit that seasonal inventory and channel mix flatter Q4 and reverse in Q1. Model the annuity, not the quarter.
Yeztugo (lenacapavir for PrEP) — the launch that matters
Yeztugo, the first twice-yearly HIV prevention injectable, posted $96M in Q4 and $150M for the partial-year 2025. Management reported 90% payer coverage achieved well ahead of the one-year target, with roughly 90% of covered individuals able to access it at $0 co-pay, and launched a direct-to-consumer "One to PrEP" campaign. The 2026 guide is ~$800M.
Assessment: Access is no longer the bottleneck; pull-through is. The gating factor now is account-by-account logistics of moving an oral-dominated PrEP market to a twice-yearly injectable, plus persistency on the second dose, which management would not yet quantify. The $96M print modestly undershot the more aggressive whispers, which is exactly why the stock wobbled after hours before recovering.
Liver disease — Livdelzi is the quiet winner
Liver sales rose 17% YoY and 3% sequentially to $844M, with the full year up 6% to $3.2B. The driver is Livdelzi in primary biliary cholangitis, which grew 42% sequentially to $150M, helped by a competitor's U.S. withdrawal that pulled switching activity forward. Gilead enters 2026 as the U.S. second-line PBC share leader at more than 50%.
"Livdelzi grew a remarkable 42% sequentially to $150 million driven by strong patient demand, further accelerated by the withdrawal of a competitor product in the US. With much of this switching activity now behind us, we are pleased to start 2026 as the US market share leader with more than 50% in second-line PBC." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer
Assessment: Livdelzi is a genuine second growth pillar inside liver, and the IDEAL Phase 3 readout later this year could expand the label into incomplete responders. The one nuance: a chunk of the 42% sequential surge was a one-time switching event, so the 2026 exit rate rather than the Q4 rate is the right anchor.
Oncology (Trodelvy) — momentum ahead of a first-line label
Trodelvy grew 8% both YoY and sequentially to $384M, beating the $362M Street estimate, and finished 2025 up 6% at $1.4B. The setup into 2026 is the story: back-to-back positive ASCENT-03 and ASCENT-04 Phase 3 readouts in first-line metastatic triple-negative breast cancer, publication in the New England Journal of Medicine, and an NCCN guideline update that makes Trodelvy the only ADC recommended in both first- and second-line metastatic TNBC.
Assessment: Trodelvy is transitioning from a single-indication second-line drug into a first-line franchise, and management already sees spontaneous (unpromoted) first-line use building. The first-line market is roughly double the second-line opportunity and carries longer duration of therapy, so approval later in 2026 is a real step-up catalyst rather than an incremental one.
Cell therapy (Kite) — the acknowledged drag
Cell therapy fell 6% YoY to $458M (though up 6% sequentially on pre-holiday treatment timing and one-time pricing) and declined 7% for the full year to $1.8B. Management guided the franchise down ~10% in 2026 on in-class and out-of-class competition plus volume erosion as more clinical trials compete for patients.
"Overall, we expect Kite revenue to decline approximately 10% in 2026 compared to 2025." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer
Assessment: Kite is a managed decline for now, and management is not sugar-coating it. The offset is the second-half potential launch of anito-cel (anidocel) in fourth-line-plus multiple myeloma, a ~$3.5B addressable market where Gilead touts a best-in-disease safety profile and 16-day manufacturing turnaround. That is a 2027 revenue story, not a 2026 one.
Key KPIs
| KPI | Q4 / FY 2025 | Prior | Trend | Read |
|---|---|---|---|---|
| Biktarvy U.S. share | >52% | rising | Up | Share gains every quarter since launch |
| Descovy PrEP U.S. share | >45% (record) | <45% | Up | Prevention market +~13% YoY |
| Yeztugo payer coverage | 90% | launching | Up | Ahead of 1-yr target; ~90% at $0 co-pay |
| Livdelzi 2L PBC share | >50% (U.S. leader) | gaining | Up | Aided by competitor withdrawal |
| FY operating margin | 45% (48% ex-items) | n/a | Stable | Expense discipline intact |
| FY non-GAAP tax rate | 18.3% | 25.9% | Down | 2024 carried a nondeductible IPR&D charge |
| Capital returned FY2025 | $5.9B (~63% of FCF) | n/a | Up | $1.9B buyback + dividend |
Key Topics & Management Commentary
Overall Management Tone: Confident and measured, with the posture of a team that believes the hard part of the transition is behind it. Management leaned on two anchors repeatedly: the breadth of the launch pipeline (up to 10 launches through 2027) and the absence of any major patent cliff until 2036. The only place the tone turned defensive was on Yeztugo persistency, where the honest answer was that it is too early to quantify refill rates.
1. The record-high stock meets an in-line guide
Gilead entered the print at a 52-week high, up 54% over twelve months, having spent 2025 re-rating on the lenacapavir prevention story and the diversification thesis finally showing up in the numbers. The 2026 guide was therefore always going to be judged against a demanding bar rather than an easy one.
Assessment: The after-hours dip was not about the quarter; it was about a guide that met, rather than exceeded, elevated expectations. That the stock recovered to a record close the next day tells you the base-business quality won the argument, but it also tells you how little cushion is left in the valuation.
2. Yeztugo: the $800M question
The centerpiece of the call. Management framed the ~$800M 2026 guide as the base of a "steady, durable, and long-term build," with all key launch indicators tracking or exceeding plan. The bull-bear tension is entirely about the shape of the curve: whether $800M is conservative (management's implied posture) or already fully reflects new-patient momentum and price.
"Given our expectations for a steady, durable and long-term build in sales, we expect full year 2026 Yeztugo revenue of approximately $800 million compared to $150 million in 2025, highlighting that Yeztugo is well on its way to achieving blockbuster status." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer
Assessment: An 5x year-on-year build to blockbuster scale in year two is a real number, and management's refusal to over-promise on persistency is the right instinct. We treat $800M as a credible floor with upside if second-dose refill rates hold, but the market has clearly already priced a good outcome.
3. Policy headwinds: quantified, not waved away
Management put numbers on the policy overhang for the first time: a ~2-point drag on 2026 HIV growth from the December drug-pricing agreement that lowers Medicaid pricing on some products (Genvoya, Odefsey) and from potential channel shifts tied to proposed ACA changes. Absent those, HIV would grow ~8% and total growth would be 6–7% rather than the guided 4–5%.
"In total, these headwinds are expected to impact HIV growth by about 2% in 2026 compared to 2025. Absent these headwinds, our HIV business is expected to grow 8% in 2026, highlighting the underlying strength of our HIV business." — Johanna Mercier, Chief Commercial and Corporate Affairs Officer
Assessment: Quantifying the headwind is a credibility positive; it lets the market separate underlying demand (healthy) from policy noise (manageable but real). The risk is that "manageable" understates the multi-year trajectory of U.S. drug-pricing policy, which is the single largest structural overhang on the name.
4. No major LOEs until 2036
The recurring refrain, and a genuine differentiator versus large-cap pharma peers staring down 2027–2030 patent cliffs. Combined with up to seven potential HIV product launches through 2033 built on the lenacapavir backbone, management is selling a decade of visibility.
"With many of the policy-related uncertainties behind us, and no major product LOEs until 2036, Gilead Sciences is entering 2026 in a position of strength." — Daniel O'Day, Chairman & CEO
Assessment: This is the strongest pillar of the long thesis and the reason a Hold is not a Sell. A clean patent runway to 2036 justifies a premium to peers facing cliffs; the question is only how much of that premium is already in a record-high stock.
5. Margin and expense discipline
SG&A fell 9% YoY in Q4 and 5% for the year even while funding the Yeztugo launch, R&D was roughly flat, and full-year operating margin held at 45% (48% excluding acquired IPR&D and a one-time IP asset sale). The 2026 guide steps gross margin to ~87% and operating income to $13.8–$14.3B.
Assessment: The cost line is a source of earnings quality here, not a risk. Management has repeatedly shown it can grow into launches without letting opex outrun revenue, and the 2026 SG&A guide (mid-single-digit growth) is disciplined given four potential launches to support.
6. Capital returns and the dividend
Gilead returned $5.9B in 2025 (about 63% of free cash flow) and raised the quarterly dividend 3.8% to $0.82. Buybacks of $1.9B were primarily aimed at offsetting dilution plus opportunistic repurchase.
Assessment: A ~2.4% yield with a well-covered payout and a commitment to return at least 50% of FCF is a floor under the stock. It is not, on its own, a reason to own a large-cap pharma at a record high, but it reduces the downside case.
7. Business development posture
Management signaled continued ~$1B/year of "normal course" early-stage deals plus disciplined openness to larger late-stage acquisitions, while stressing there is no urgency given the internal pipeline.
"We may not have the urgency of other companies in this sector... But I would say that we very much want to continue to add to our pipeline with appropriate M&A over the course of the coming years as well." — Daniel O'Day, Chairman & CEO
Assessment: The "no urgency" framing cuts both ways. It reassures on capital discipline (no forced, dilutive megadeal to fill a cliff), but it also means the next leg of growth leans heavily on execution of the existing pipeline rather than an inorganic catalyst.
8. Trodelvy's move to first line
Two positive Phase 3 readouts, an NCCN update, and building spontaneous first-line use set up a first-line metastatic TNBC launch later in 2026, with the first-line opportunity roughly double second-line and carrying longer duration of therapy.
Assessment: This is the most tangible near-term growth optionality outside HIV. It de-risks the oncology leg of the diversification thesis and gives the 2026 revenue guide a credible upside path if approval and uptake land on schedule.
9. Anito-cel and the Kite offset
The anito-cel (anidocel) BCMA CAR-T filing in fourth-line-plus multiple myeloma showed a 96% overall response and 74% complete response with a differentiated neurotoxicity/enterocolitis profile, targeting a ~$3.5B market with a potential second-half launch.
Assessment: Anito-cel is the reason to keep the faith in Kite, but management was clear the 2026 contribution is modest, with a full year of sales only in 2027. It reframes cell therapy from terminal decline to trough-and-recover, which matters for the multi-year thesis more than the 2026 model.
10. The long-acting HIV pipeline
Beyond Yeztugo, Gilead is advancing a weekly oral (islatravir + lenacapavir), a once-daily oral (Viclen / BIC-LEN, with ARTISTRY-1/2 positive), and a twice-yearly treatment (GS-3242 prioritized), positioning lenacapavir as the backbone of up to seven launches through 2033.
Assessment: The breadth here is the structural moat. Whether or not any single asset dominates, the portfolio approach across daily/weekly/monthly/twice-yearly dosing is difficult for competitors relying on single products to match, and it underpins the 2036-LOE claim.
Guidance & Outlook
| Metric (FY2026 guide) | Guidance | Street | Read |
|---|---|---|---|
| Total product sales | $29.6B–$30.0B | $30.04B | Low end / slightly light |
| Base business (ex-Veklury) | $29.0B–$29.4B (+4–5%) | n/a | In line |
| Veklury | ~$600M | ~$600M | In line ($300M headwind) |
| Non-GAAP operating income | $13.8B–$14.3B | n/a | n/a |
| Non-GAAP EPS | $8.45–$8.85 (mid $8.65) | $8.61 | Roughly in line |
| Product gross margin | ~87% | n/a | Up ~1pt |
| Tax rate | ~20% | n/a | Up from 18.3% |
| HIV growth | ~6% (8% ex-headwind) | n/a | ~2pt policy drag |
| Yeztugo | ~$800M | varies | From $150M |
| Cell therapy | ~-10% | n/a | Competitive |
The guide is the whole debate. On revenue, the $29.8B midpoint sits just below the ~$30.04B Street number, and management is candid that a ~2-point policy headwind plus a $300M Veklury step-down are the reason underlying 6–7% growth compresses to a reported 4–5%. On earnings, the $8.65 EPS midpoint is essentially on top of the $8.61 consensus, with the higher ~20% tax rate offsetting the ~87% gross margin step-up. This is not a disappointing guide; it is a realistic one, and the initial after-hours reaction reflected a market that wanted more headroom rather than realism.
Implied ramp: The 4–5% base-business guide leans on HIV (~6% reported), Trodelvy's first-line launch, and continued Livdelzi share, partly offset by a ~10% Kite decline and the Veklury drag. Yeztugo's $650M year-on-year step-up is roughly half the incremental base-business dollars, which is why the persistency question dominated Q&A.
Guidance style: Consistent with Gilead's pattern of guiding to a defensible base and beating on execution. Full-year 2025 product sales came in above the guided range, and management's framing of Yeztugo as a "floor" plus the conservative-looking $800M number suggest the same setup into 2026.
Analyst Q&A Highlights
The $800M Yeztugo build and refill economics
The opening exchange, and the dominant topic of the call, probed the assumptions inside the $800M guide and, critically, what the company assumes for second-dose refill rates now that the earliest patients are due for redosing. Management leaned into access metrics but declined to put a number on persistency, calling it too early.
Q: "Can you just elaborate a little bit more on the assumptions driving the $800 million guidance? And maybe as part of that, as we start to think about patients now needing to be redosed on the drug, what type of refill rates are you anticipating?"
— Chris Schott, JPMorgan
A: "All of our key launch indicators are basically tracking or exceeding our expectation... about 90% payer coverage... About 90% of those with $0 co-pay. To your point around persistency, we don't have an assumption at this point in time because it's still really quite early."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer
Assessment: The honest "no persistency assumption yet" is both reassuring (guidance isn't built on a heroic refill number) and the crux of the risk (the biggest driver of 2027+ is unquantified). It is the single most important open variable in the model.
Descovy cannibalization and net-price decay
A recurring line of questioning pressed whether Yeztugo will begin eating Descovy PrEP sales this year and how net price evolves through the launch. Management argued both brands grow in 2026, with Descovy erosion a later-cycle event.
Q: "Are you expecting to begin to see cannibalization of Descovy PrEP sales as early as this year? And how should we be thinking about the evolution of net price for Yeztugo throughout the launch?"
— Tazeen Ahmad, Bank of America
A: "We believe Descovy will continue to grow through 2026 and over time, of course, that will erode as Yeztugo takes a leading share in HIV prevention... Yeztugo's value proposition is quite differentiated and we feel strongly that that is being recognized."
— Johanna Mercier, Chief Commercial and Corporate Affairs Officer
Assessment: The "all boats rise in 2026" answer is credible for now given a ~13% growing prevention market, but investors should model Descovy erosion as a 2027+ headwind. The refusal to discuss gross-to-net is standard, but it leaves net-price trajectory as a second unquantified variable.
Anito-cel share in fourth-line myeloma
Questioning focused on how much share a late-2026 anito-cel launch can take against entrenched BCMA competitors, and what confidence supports a second-half launch. Management pointed to a differentiated safety profile and manufacturing reliability but conceded modest 2026 contribution.
Q: "What type of share gains do you expect for anito-cel in the fourth-line setting if you're approved, especially in light of competition from entrenched players?"
— Louise Chen, Scotiabank
A: "The market for fourth-line multiple myeloma is a $3.5 billion market. We expect, because the launch is the second half of the year... modest contribution in 2026. However, in 2027, we will have a full year of sales. We expect over time to become the market leader given our excellent efficacy profile and differentiated safety profile."
— Cindy Perettie, EVP, Kite
Assessment: The 16-day turnaround and 99% reliability are genuine competitive advantages in CAR-T, where manufacturing failures are common. But this is explicitly a 2027 revenue story; it does not rescue the 2026 Kite decline.
GS-3242 and the twice-yearly treatment race
A question compared Gilead's long-acting twice-yearly treatment program against competitor efforts, asking what excites management about the GS-3242 INSTI profile. The answer stressed portfolio breadth and the strategic importance of an integrase inhibitor in the combination.
Q: "Can you tell us a little bit about the profile of that drug and what you're seeing in Phase 1 to get you excited?... How do you compare that to Shionogi's product?"
— Michael Yee, UBS
A: "3242 is obviously a long-acting INSTI. We firmly believe that an integrase inhibitor is important in this combination, and think that also sets it apart from some of the other options... please keep in mind that they cannot base once-every-six-months treatment on one product only. They all need a combination."
— Dietmar Berger, Chief Medical Officer
Assessment: Management's competitive argument (two lenacapavir-based programs plus the INSTI mechanism) is credible, and it reinforces the "backbone" narrative. This is a 2028+ catalyst, so it supports the long-duration thesis rather than the 2026 model.
Once-yearly lenacapavir PrEP (PURPOSE 365)
Questioning explored what the PURPOSE 365 study needs to show to support a once-yearly PrEP option and how it would be positioned. Management described a PK-based study and framed annual dosing as a market-expansion opportunity.
Q: "Can you maybe just talk about what you need to show out of PURPOSE 365 in order to support approval, and how you're planning to position that in the market if successful?"
— Brian Abrahams, RBC Capital Markets
A: "PURPOSE 365 is a PK-based study. It's a smaller study... where we basically need to demonstrate target coverage and the right pharmacokinetics... it can really bring in a very important benefit with a longer-term interval." Management added it "could be available as early as 2028."
— Dietmar Berger, Chief Medical Officer
Assessment: A once-yearly option would meaningfully broaden the addressable PrEP population (including harder-to-reach and unstably-housed patients). It is a long-dated catalyst, but it is exactly the kind of optionality that supports paying a premium for the lenacapavir platform over time.
Trodelvy endometrial Phase 3 timing and confidence
A question flagged the second-half ASCENT GYN-01 endometrial readout as likely an interim analysis and asked about confidence and market size. Management pointed to encouraging Phase 2 data while framing endometrial as incremental relative to TNBC.
Q: "Can you speak to your confidence overall heading into this interim? And is it fair to say that the size of the indication is generally similar with triple-negative breast?"
— Umer Raffat, Evercore ISI
A: "We are primarily intrigued about endometrial because of the earlier study... where we saw a median OS of fifteen months in that population... Second-line endometrial cancer is of course more of an incremental opportunity." Management sized the addressable population at roughly 5,000 in the U.S.
— Dietmar Berger, Chief Medical Officer
Assessment: A measured, non-promotional answer that right-sizes endometrial as incremental. The bigger oncology optionality remains first-line TNBC and the EVOQUE-03 lung readout; endometrial is a bonus, not a pillar.
Business development urgency and portfolio voids
A bigger-picture question asked what strategic voids management sees and whether there is any BD urgency given the pipeline turnover. The answer emphasized discipline and the absence of a cliff-driven need to transact.
Q: "You haven't done a larger-scale deal in a while. So I wanted to get a sense as to what voids you think you need to fill... or is there no real BD urgency from you guys at this point?"
— Geoffrey Meacham, Citi
A: "As we approach later-stage acquisitions, we do it in the context of the fact that we have the most robust clinical and launch pipeline in our company's history with no major LOEs until 2036. So we're uniquely positioned... But we may not have the urgency of other companies in this sector."
— Daniel O'Day, Chairman & CEO
Assessment: The "no urgency, but stay active" posture is the right capital-allocation stance and lowers the risk of a value-destructive megadeal. It also means investors should not underwrite a transformational acquisition as part of the near-term thesis.
What They're NOT Saying
- Yeztugo persistency/refill rate: Management explicitly declined to give a second-dose refill assumption. Because refills compound the revenue base of a twice-yearly drug, this omission is the largest unquantified driver of the 2027+ trajectory.
- Gross-to-net for Yeztugo: No net-price disclosure. Given the questions about price decay over the launch and the Descovy comparison, the silence leaves the durability of Yeztugo's realized price an open question.
- Quarterly cadence of the 2026 guide: Beyond flagging the Q1 seasonal HIV drawdown, management gave little quarterly shape. With a ~2-point policy headwind phasing in and Trodelvy's first-line launch mid-year, the intra-year path is lumpier than the full-year guide implies.
- Magnitude of the ACA/MFN headwind beyond 2026: The ~2-point figure is a 2026 number. Management did not frame the multi-year path of U.S. drug-pricing policy, which is the structural overhang investors most want sized.
- Specific first-line Trodelvy launch timing and peak: Management confirmed FDA decisions are expected in 2026 but did not commit to a launch quarter or a peak-sales frame for the first-line opportunity, leaving the biggest oncology catalyst loosely defined.
Market Reaction
- Pre-print setup: GILD closed at $147.23 entering the print, up 20.0% YTD, up 21.6% over the trailing 30 days, and up 54.2% over the trailing twelve months, sitting essentially at the top of its 52-week closing range ($95.48–$152.50). Options had implied roughly a 5% event move.
- After-hours move: Shares fell as much as ~5.8% in extended trading on Feb 10 as the market keyed on a 2026 revenue guide at the low end of Street models and a $96M Yeztugo print shy of the more aggressive whispers.
- Reaction session (Feb 11): The dip reversed hard. The stock gapped up ~1.1%, ran to an intraday high of $157.29, and closed at a record $155.80, up 5.8% on the day (a +$8.57 move) on 1.6x average volume, as analysts boosted forecasts and the Street re-read the print as a clean base-business beat. The S&P 500 was roughly flat that session, so the move was idiosyncratic.
The 12-hour round trip from a 5.8% after-hours drop to a 5.8% record-high close is the tell. The initial reaction was a reflex to a guide that met rather than beat a demanding bar; the recovery was recognition that the base business is high quality, the EPS guide is in line, gross margin is stepping up, and Yeztugo's number looks conservative. Net, the tape validated the fundamentals but also demonstrated how quickly the stock trades on guidance psychology at a full valuation.
Street Perspective
Debate: Is $800M Yeztugo conservative or already priced?
Bull view: With 90% payer coverage achieved months ahead of plan, a growing prevention market, and a DTC campaign just launched, the guide looks like a sandbagged floor with clear upside as pull-through accelerates through the year.
Bear view: The $96M Q4 print undershot the more aggressive whispers, persistency is unproven, and the stock's record-high valuation already embeds a strong launch, leaving little reward for an in-line outcome and real downside on any stumble.
Our take: The bull case on the number is stronger than the bull case on the stock. We think $800M is beatable, but at a record high the beat may already be in the price.
Debate: Does the 2036 LOE runway justify a premium multiple?
Bull view: A clean patent runway to 2036 plus up to 10 launches through 2027 is a scarcity asset among large-cap pharma peers facing 2027–2030 cliffs, and deserves a premium the market has only begun to award.
Bear view: Mid-single-digit base-business growth, a ~2-point policy headwind, and a declining Kite franchise cap the growth rate regardless of the LOE runway; a durable-but-slow compounder should not trade like a growth name.
Our take: The runway justifies a premium to cliff-exposed peers, but not an unlimited one. At ~18x the 2026 EPS midpoint, the premium is fair, not cheap, which is the core of our Hold.
Debate: How big is the U.S. drug-pricing overhang?
Bull view: Management quantified the 2026 hit at ~2 points and called the pricing agreement "manageable," and much of the policy uncertainty is now behind the company; the base business grows through it.
Bear view: Medicaid pricing concessions, ACA subsidy expiry, and most-favored-nation dynamics are the leading edge of a multi-year policy trend, and a company with 70%+ of sales in HIV is disproportionately exposed to U.S. pricing risk.
Our take: The 2026 impact is manageable; the multi-year path is the real overhang and the hardest thing to underwrite. This is the single biggest reason we are not paying up today.
Model Update Needed
| Item | Prior frame | Post-print | Reason |
|---|---|---|---|
| 2026 product sales | ~$30.0B (Street) | $29.6B–$30.0B (mid $29.8B) | Policy + Veklury drag; underlying 6–7% |
| 2026 non-GAAP EPS | ~$8.61 | $8.45–$8.85 (mid $8.65) | ~87% GM offset by ~20% tax |
| Yeztugo 2026 | launch ramp | ~$800M (treat as floor) | 90% coverage; persistency not yet established |
| Cell therapy 2026 | stabilizing | ~-10% | In/out-of-class competition |
| Gross margin | ~86.4% | ~87% | Mix + discipline |
| Capital return | ~50% of FCF | ≥50% of FCF; div +3.8% | $0.82 quarterly dividend |
Valuation impact: At a $155.80 record close, GILD trades at roughly 18x the 2026 EPS midpoint of $8.65. That is a fair multiple for a de-risked large-cap with a 2036 LOE runway and a ~2.4% yield, but it already reflects the good news. We see the fair-value band roughly around the mid-$150s to low-$160s and would need either a pullback toward the low-$140s or a guidance raise to see enough relative upside versus the S&P to move off Hold.
Thesis Scorecard Post-Earnings (Initiation)
| Thesis Point | Status | Notes |
|---|---|---|
| Bull #1 — HIV durability + prevention supercycle | Confirmed | Record $5.8B HIV quarter; Biktarvy >52% share; Descovy +33%; Yeztugo at 90% coverage |
| Bull #2 — Diversification (liver + oncology) delivering | Confirmed | Livdelzi >50% 2L PBC; Trodelvy beat and moving to first line |
| Bull #3 — Cash generation + 2036 LOE runway | Confirmed | $5.9B returned (63% of FCF); dividend +3.8%; no LOE until 2036 |
| Bear #1 — U.S. drug-pricing / policy overhang | Emerging | ~2pt 2026 HIV drag quantified; multi-year path unsized |
| Bear #2 — Kite cell therapy secular decline | Materializing | -7% in 2025; guided ~-10% in 2026; anito-cel is a 2027 offset |
| Bear #3 — Full valuation after +54% TTM run | Emerging | Record high above median PT; in-line guide leaves little cushion |
Overall: The operating thesis is confirmed on every pillar; the constraint is price, not fundamentals. This is a high-quality, de-risked franchise that has already been substantially re-rated.
Action: Initiate at Hold. Own the quality, but wait for a better entry (low-$140s) or a guidance raise before adding. We would turn more constructive if Yeztugo runs ahead of the $800M floor and the stock has not fully anticipated it.